Mayne Pharma Ord

0.2041-0.0276-11.91%Vol 1.90K1Y Perf -26.32%
Nov 24th, 2021 11:52
BID0.0000 ASK0.0000
Open0.2103 Previous Close0.2317
Pre-Market- After-Market-
 - -%  - -
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     51.91
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
+     30.84
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
6.97 
Earnings Rating
Market Cap- 
Earnings Date
-
Alpha-0.04 Standard Deviation0.13
Beta1.39 

Today's Price Range

0.20410.2103

52W Range

0.18800.4190

5 Year PE Ratio Range

-5.200045.700

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-13.00%
1 Month
-18.81%
3 Months
8.56%
6 Months
-30.81%
1 Year
-26.32%
3 Years
-74.10%
5 Years
-82.85%
10 Years
0.00%

TickerPriceChg.Chg.%
MAYNF0.2041-0.0276-11.91
AAPL156.81-5.1300-3.17
GOOG2 856.12-78.2300-2.67
MSFT329.68-8.2300-2.44
XOM61.25-2.2300-3.51
WFC48.43-2.8800-5.61
JNJ159.20-1.0400-0.65
FB333.12-7.9400-2.33
GE97.84-4.3900-4.29
JPM161.93-5.0300-3.01
Financial StrengthValueIndustryS&P 500US Markets
1.30
1.90
0.28
0.45
-7.20
Leverage Ratio 1.90
ProfitabilityValueIndustryS&P 500US Markets
48.70
-57.80
-40.80
-25.30
-52.23
RevenueValueIndustryS&P 500US Markets
289.33M
0.16
-6.24
14.69
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.90K
Shares Outstanding0
Shares Float1.76B
Trades Count2
Dollar Volume393
Avg. Volume19.65K
Avg. Weekly Volume124.36K
Avg. Monthly Volume38.40K
Avg. Quarterly Volume31.60K
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Mayne Pharma Ord

Mayne Pharma is a small generics and specialty pharmaceutical manufacturer that earns over 90% of revenue in the U.S. market. Product portfolios focus on dermatology and women's health. The company performs very limited research and development, typically acquiring off-patent or tail-end brands. In fiscal 2019 generics contributed 61% of revenue and specialty brands 17%, with the balance coming from non-U.S. sales and contract manufacturing. Dynamics within the U.S. generics market leading to increased competition and significant drug price declines have resulted in Mayne significantly impairing acquired intangible assets. The company is shifting its focus to growth of the higher-margin specialty brands segment.

CEO:

Telephone: +61 882092666

Address: 1538 Main North Road, Salisbury 5106, SA, AUS

Number of employees: 160

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

57%43%

Bearish Bullish

50%50%

News